ClinicalTrials.gg

Rosacea clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 233 studies for Rosacea across more than 10 countries. 22 are recruiting or about to start. 205 of them are mainly about Rosacea (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
176
Recruiting
16
Status unknown
16
Withdrawn
9
Terminated
8
Not yet recruiting
3

Phase

Phase 2
58
Phase 3
43
Phase 1
28
Phase 4
27
Early Phase 1
4

Where

United States
145
Canada
17
China
16
Germany
14
France
11
United Kingdom
6

Who develops what

Add Rosacea to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 3 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Novartis and Sun Pharmaceutical Industries here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DoxycyclineRecent, limited
Evidence
  • NCT05343455 · Journey Medical Corporation · Phase 3 · comparator · “Doxycycline” · registered Apr 2022
  • NCT05296629 · Journey Medical Corporation · Phase 3 · comparator · “Doxycycline” · registered Mar 2022
  • NCT00855595 · LEO Pharma · Phase 4 · background · “Doxycycline (Oracea)” · registered Mar 2009
Galderma Group AG25% of its industry studiesUS: off-patent, 66 generics marketed12 studies
MetronidazoleEarlier only
Evidence
  • NCT01493947 · Galderma Group AG · Phase 3 · comparator · “Metronidazole 0.75% cream” · registered Dec 2011
  • NCT01449591 · Novartis · Phase 2 · comparator · “Noritate® 1% cream” · registered Sep 2011
  • NCT00855595 · LEO Pharma · Phase 4 · comparator · “Metronidazole (Metrogel)” · registered Mar 2009
Pfizer22% of its industry studiesUS: off-patent, 37 generics marketed00 studies
IvermectinEarlier only
Evidence
  • NCT03075891 · Galderma Group AG · Phase 4 · background · “Ivermectin 1% cream” · registered Mar 2017
  • NCT02795117 · padagis · Phase 3 · comparator · “Ivermectin (reference)” · registered Jun 2016
Galderma Group AG21% of its industry studiesUS: off-patent, 10 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.lotilaner · Tarsus Pharmaceuticals, Inc. · Phase 2 main aimNCT07443202 Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) — primary endpoint: Incidence of Treatment Emergent Adverse Events · 155 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Rosacea studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open

Coming up

0phase 3 studies under way
9studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger. 1 (6%) take children under 18. 2 (13%) are for women only and 0 (0%) for men only; 8 (50%) take healthy volunteers.

Recruiting studies that take each age, of 16
AgeWomenMen
101 (6%)1 (6%)
1813 (81%)13 (81%)
3015 (94%)14 (88%)
4016 (100%)14 (88%)
5016 (100%)14 (88%)
6513 (81%)13 (81%)
7510 (63%)10 (63%)
859 (56%)9 (56%)

Across all 233 studies, recruiting or not: 33% stop at 75 or younger and 24% at 65; 4% take children; 4% are for women only and <1% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Rosacea studies take

Of 20 phase 2 interventional studies under Rosacea, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 18 mo5–13 · 13 studies——
Phase 212 mo7–16 · 20 studies——
Phase 311 mo9–15 · 17 studies——
Phase 413 mo6–21 · 12 studies——
Interventional, no phase11 mo6–29 · 42 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 233. Browse all 233 → or search them.